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Background: The actin cytoskeleton in podocytes is essential for the maintenance of its normal structure
and function. Its disruption is a feature of podocyte foot-process effacement and is associated with
proteinuria. a-Actinin-4 in podocytes serves as a linker protein binding the actin ﬁlaments of the
cytoskeleton.
Methods: To investigate the effect of ginseng total saponin (GTS) on the pathological changes of podocyte
a-actinin-4 induced by diabetic conditions, we cultured mouse podocytes under normal glucose (5mM)
or high glucose (HG, 30mM) conditions, with or without the addition of advanced glycosylation end
products (AGE), and treated with GTS.
Results: In confocal imaging, a-actinin-4 colocalized with the ends of F-actin ﬁbers in cytoplasm, but
diabetic conditions disrupted F-actin ﬁbers and concentrated a-actinin-4 molecules at the peripheral
cytoplasm. GTS upregulated a-actinin protein in a time- and dose-dependent manner, and suppressed
the receptor for AGE levels in western blotting. Diabetic conditions, including HG, AGE, and both
together, decreased cellular a-actinin-4 protein levels at 24 h and 48 h. Such quantitative and qualitative
changes of a-actinin-4 protein induced by diabetic conditions were mitigated by GTS.
Conclusion: These ﬁndings imply that both HG and AGE have an inﬂuence on the distribution and
amount of a-actinin-4 in podocytes that can be recovered by GTS.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Diabetic nephropathy is a serious chronic complication of dia-
betes mellitus that affects around 30% of diabetic patients and is the
most common cause of end-stage renal disease in the Western
world [1]. Early glomerular pathological changes of diabetic ne-
phropathy include glomerular hypertrophy, an increase in mesan-
gial matrix, thickening of the glomerular basement membrane
(GBM), and morphological changes of podocytes such as efface-
ment, denudation, and loss, which manifest as hyperﬁltration and
microalbuminuria [1,2]. Diabetic renal changes are characterized by
a progressive loss of renal function, oxidative stress, chronic
inﬂammation, vascular remodeling, glomerulosclerosis, tubu-
lointerstitial ﬁbrosis, and overt proteinuria [1,2]. These pathological
and hemodynamic changes are caused by biochemical alterations,
including hyperglycemia, secondary glycated proteins, orCollege of Medicine, Chungbuk Na
erms of the Creative Commons At
ribution, and reproduction in any
e Korean Society of Ginseng, Publirreversible advanced glycosylation end products (AGEs), leading to
an increase in glomerular permeability as a result of the impaired
glomerular ﬁltration structure [3e5].
The glomerular capillary is a knot of specialized capillaries with
a fairly high pressure ﬂow (60 mmHg), and are an efﬁcient and
selective barrier allowing the ﬁltration of large amounts of plasma
and small solutes into the urinary space. The glomerular-slit dia-
phragm, a slit between the interdigitating foot processes of podo-
cytes, serves as a size-selective barrier and is linked to the actin-
based cytoskeleton by adaptor proteins [6e10]. The podocyte foot
processes contain a dense network of actin ﬁlaments, which are
linked by linker proteins, such as a-actinin-4, synaptopodin, and
cortactin [6e11]. The a-actinin molecule is an elongated, sym-
metrical, and antiparallel dimeric rod with actin-binding sites at
either end that enables cross-linkage of F-actin ﬁlaments into
contractile bundles [10,12] and forms an anchoring complex for thetional University, Cheongju 361-763, Korea.
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
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Fig. 1. Localization of a-actinin-4 and F-actin in podocytes. (A) Fluorescence spots of a-actinin-4 are located in the peripheral cytoplasm and processes of podocytes and are co-
localized at the terminal ends of actin ﬁlaments. Diabetic conditions tend to concentrate a-actinin-4 staining at the peripheral cytoplasm (arrows) and disrupt F-actin ﬁbers (arrow
heads). (B) Ginseng total saponin (GTS, 1 mg/mL) improves the distributional changes of a-actinin-4 and F-actin ﬁbers induced by diabetic conditions. (Scale: 400.) DAPI, 40 ,6-
diamidino-2-phenylindole dihydrochloride.
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the four highly homologous a-actinin molecules, nonmuscle type
a-actinin-4 is highly expressed at the foot processes of the podo-
cytes and is required for normal podocyte adhesion [11,13].
Ginseng has been reported to be effective in the prevention and
treatment of diabetic nephropathy in type 1 and type 2 diabetic
animal models. In type 1 insulin-dependent diabetic nephropathy
induced by streptozotocin animal models, Sun ginseng [14], heat-
processed American ginseng [15], 20(S)-ginsenoside Rg3 [16], and
Korean Red Ginseng (KRG) [17] ameliorated elevated serum
glucose and renal damage. In particular, KRG ameliorated abnor-
malities associated with diabetic nephropathy through suppres-
sion of the inﬂammatory pathways activated by tumor necrosis
factor-a and AGE [17]. In type 2 insulin-resistant diabetic ne-
phropathy animal models, 20(S)-ginsenoside Rg3 decreased theelevated blood glucose and proteinuria, and augmented creatinine
clearance in type 2 diabetic Otsuka Long-Evans Tokushima Fatty
rats [18].
Although the renoprotective effect of ginseng components in
diabetic models has been reported, there are a few reports that
have attempted to elucidate the changes of the podocyte cyto-
skeleton in diabetes. Recently, we reported that in vitro diabetic
conditions induced the distributional change and suppressed the
production of adaptor proteins, such as ZO-1 [19], p130Cas [20], and
b-catenin [21], thus causing the phenotypical changes and hyper-
permeability of podocytes, which could be rescued by ginseng total
saponin (GTS) [19e21].
In this study, we investigated the effect of GTS on the patho-
logical changes of podocyte cytoskeletal a-actinin-4, an important
cytoskeletal linker protein, induced by diabetic conditions.
Fig. 2. Effects of ginseng total saponin (GTS) on the a-actinin-4 protein and receptor for advanced glycosylation end products (RAGE) assayed by western blotting. (A) GTS
upregulates a-actinin in a dose-dependent manner. (B) GTS downregulates RAGE levels in podocytes. Data on the densitometric analysis of a-actinin-4 or RAGE/b-tubulin ratio are
expressed as mean  standard deviation (n ¼ 3). Control (100%), the value without GTS condition. *p < 0.05 and **p < 0.01 versus control.
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2.1. Cell culture of mouse podocytes
Conditionally immortalized mouse podocytes were kindly pro-
vided by Dr Peter Mundel (University of Harvard, Boston, MA, USA)
and were cultured and differentiated as described previously [22].
Brieﬂy, cells were cultivated at 33C (permissive conditions) in a
culture medium supplemented with 10 U/mL mouse recombinant
g-interferon (Roche, Mannheim, Germany) to induce the expres-
sion of temperature-sensitive large T antigens for proliferation. To
induce differentiation, podocytes were maintained at 37C without
g-interferon (non-permissive conditions) for at least 2 wk.2.2. Culture additives
Mouse podocytes were serum-deprived to reduce the back-
ground of serum 24 h before each experiment. The podocytes were
then exposed to glucose and/or AGEs. Cells were incubated in
culture medium containing either 5mM glucose (normal glucose)
or 30mM glucose (high glucose, HG) without insulin. AGEs were
produced by a technique previously described by Ha et al [23]. To
imitate a long-term diabetic condition, AGEs were added (5 mg/mL)
and controls were established using unmodiﬁed bovine serum al-
bumin (5 mg/mL). To exclude the effect of additionally produced
glycated proteins during culturing, incubation did not last longer
than 48 h. For identiﬁcation purposes, AGEs and bovine serum al-
bumin are denoted as A and B, and 5mM and 30mM glucose are
denoted as 5 and 30, respectively. Brieﬂy, B5 is normal, B30 is a
short-term diabetic condition, A5 is a long-term normoglycemic or
aged condition, and A30 is a long-term diabetic condition.
For ginseng treatment, podocytes were incubated with GTS at
various concentrations (0.2, 1, 5, 25 mg/mL) for 6 h, 24 h, and 48 h.
GTS was kindly provided by the Korea Ginseng Corporation (Dae-
jeon, Korea).2.3. Confocal image analysis
Podocytes that were grown on type I collagen-coated glass
cover slips incubated for 24 h were ﬁxed in 4% paraformaldehyde,
permeabilized in a phosphate buffer solution, blocked with 10%
normal goat serum, and labeled with polyclonal goat antimouse a-
actinin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Primary antibody-bound specimens were incubated with 1:500
(v/v) Alexa 488 (Molecular Probes, Invitrogen, Eugene, OR, USA)
conjugated secondary antibodies at room temperature for 1 h. F-
actin was visualized with TRITC-phalloidin (Sigma Chemical, St.
Louis, MO, USA) and nuclei were stained with 2mM 40,6-dia-
midino-2-phenylindole dihydrochloride (Sigma Chemical). Cov-
erslips were mounted in an aqueous mounting medium and
viewed with a ﬂuorescence microscope (BX51, OLYMPUS, Tokyo,
Japan).2.4. Western blotting
The conﬂuently-grown cell layers incubated with additives for
a-actinin and various durations for AGE were extracted, and then
the protein concentrations were determined as previously
described [23]. For the western blotting of a-actinin and the re-
ceptor for AGE (RAGE), 30 mg of boiled extracts were applied to
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
gels (Bio-Rad Laboratories, Hercules, CA, USA) and transferred to
polyvinylidene ﬂuoride membranes. Then, the membranes were
air-dried and blocked in 3% fat-free milk before incubation with
antia-actinin antibody or antiRAGE antibody (Santa Cruz
Biotechnology). After incubation with horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology),
bands were detected using the ECL chemiluminescence system
(Amersham Biotech Ltd., Bucks, UK). Data on the densitometric
analysis of respective proteins/b-tubulin ratio are expressed as
mean  standard deviation.
Fig. 3. Effects of diabetic conditions and ginseng total saponin (GTS) on the a-actinin-4
protein assayed by western blotting. (A) The bands for a-actinin protein at 100 kDa
were compared with those of b-tubulin. (B) After 24 hours of incubation time, high
glucose (B30), advanced glycosylation end products (AGE) (A5), or high glucose plus
AGE (A30) conditions signiﬁcantly suppress the amount of a-actinin protein. (C) Re-
sults on B5 and A30 were compared according to the exposure times. Data on the
densitometric analysis of the a-actinin/b-tubulin ratio are expressed as
mean  standard deviation (n ¼ 3). Control (100%) the value of the B5. *p < 0.05
versus. control.
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The results are presented as mean values  standard deviation,
as required under different conditions. The statistical signiﬁcance
was assessed using a nonparametric Kruskal-Wallis analysis of
varience or Student t test using the SPSS 9.0.0 (SPSS, Chicago, IL,
USA) software program. A p-value < 0.05 was considered
signiﬁcant.
3. Results
3.1. Confocal image changes of a-actinin
The a-actinin staining, located in the peripheral cytoplasm and
processes of podocytes, was co-localized at the terminal ends of
actin ﬁlaments. Diabetic conditions, especially in more pathological
A30 at 24 h, concentrated a-actinin-4 staining of the peripheral
cytoplasm and disrupted F-actin ﬁbers (Fig. 1A). Such distributional
change of a-actinin-4 and F-actin ﬁbers was reversed by 1 mg/mL of
GTS (Fig. 1B).
3.2. Effects of GTS on podocyte a-actinin and RAGE
In western blotting, GTS signiﬁcantly (p < 0.05) upregulated the
a-actinin-4 protein of the podocytes at longer durations (24 h and
48 h) in a dose-dependent manner compared with the control (B5)
(Fig. 2A). GTS also downregulated RAGE levels in podocytes by
28.1% (p < 0.05) compared with B5 (Fig. 2B). GTS therefore might
have a positive inﬂuence on the a-actinin protein of podocytes
partly by inhibiting RAGE expression.
3.3. Western blotting of a-actinin in cultured podocyte
The bands for a-actinin protein at 100 kDa were compared to
those of b-tubulin. Density values for the a-actinin protein of
representative immunoblots from each group revealed that HG
(B30) suppressed the amount of a-actinin protein by 26.8% at 24 h
and 24.1% at 48 h. These reductions were signiﬁcant when
compared with the control (B5). AGE (A5) alone or HG and AGE
(A30) conditions also signiﬁcantly suppressed the amount of a-
actinin protein at 24 h and 48 h (p < 0.05) compared with B5 at 6 h
after correcting for the b-tubulin levels (Figs. 3A and 3B). GTS (1 mg/
mL) rescued the quantitative changes in the amount of a-actinin
protein induced by diabetic conditions at 48 h (p< 0.05). Results on
B5 and A30 podocytes were compared according to the exposure
times given in Fig. 3C. These observations suggest that both HG and
AGE induced cytoplasmic relocalization and concentration and
suppressed the production of a-actinin-4 in an in vitro diabetic
milieu, which could be mitigated by GTS (Fig. 4).
4. Discussion
The podocyte consists of a cell body, major processes, secondary
processes, and ﬁnely interdigitating foot processes [10,11]. The
podocyte cell body andmajor and secondary foot processes contain
vimentin-rich intermediate ﬁlaments, and the larger microtubules
form organized structures along themajor and secondary processes
[10,11,24]. The podocyte foot processes contain long, dense actin
ﬁber bundles that run cortically and contiguously to link adjacent
processes and are connectedwith an array of linker proteins to both
the slit diaphragm and the GBM anchor proteins [8e11]. These
interactions are an essential prerequisite to maintain the highly
ordered foot process architecture, and hence the ﬁltration barrier.
The foot process effacement, a morphological change in proteinuric
conditions, including advanced diabetic nephropathy, leads to
Fig. 4. Schematic view of cytoskeletal changes in the podocyte. Both high glucose and advanced glycosylation end products (AGE) induce the inner cytoplasmic relocalization and
suppress the production of a-actinin-4 with the disruption of actin ﬁbers, which were mitigated by ginseng total saponin (GTS).
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mobilization of the cell-matrix contacts [8,25].
The actin ﬁlaments of the podocyte foot processes are linked by
linker proteins, such as a-actinin-4, synaptopodin, and cortactin
[6e11]. The a-actinin molecule is an elongated, symmetrical, and
anti-parallel dimeric rod with actin-binding sites at focal contacts
on the plasma membrane that enable cross-linkage of F-actin ﬁla-
ments into contractile bundles [10,12,26]. The a-actinin molecule is
highly expressed in podocytes and is required for normal podocyte
adhesion.
A form of human familial autosomal-dominant focal and
segmental glomerulosclerosis is known to be associated with
function mutations of the ACTN4 gene. The mutant actinins showed
increased F-actin afﬁnity [13], and a-actinin-4 was noted as a key
molecule in maintaining podocyte cytoskeletal integrity in physi-
ological and pathological conditions. Knockout [27] and transgenic
studies [28] have also emphasized the critical role of a-actinin-4 in
maintaining podocyte integrity in animals. These genetic results
demonstrate that podocyte damage and proteinuria can result from
cytoskeletal alterations. The fact that loss-of-function mutations
can lead to proteinuria and focal and segmental glomerulosclerosis
supports further investigation of the subtle inherited and acquired
changes in a-actinin-4 that may be involved in the development of
human and animal kidney diseases. We reported that in vitro both
HG and AGE can induce cytoplasmic relocalization and condensa-
tion and also suppress the production of a-actinin-4 at the tran-
scriptional level. These changes may explain the cytoskeletal
changes of the podocyte in diabetic conditions [12]. The results
reported by Ha [12] relating to podocyte a-actinin-4 are similar to
this study and are mitigated by GTS.
Ginseng has been reported to be effective in the prevention
and treatment of diabetic nephropathy of type 1 diabetic animal
models. Sun ginseng [14], heat-processed American ginseng [15],
20(S)-ginsenoside Rg3 [16], and KRG [17] ameliorated elevated
serum glucose and renal damage in streptozotocin-induced type
1 insulin-dependent diabetic nephropathy animal models. In
particular, KRG decreased serum glucose and signiﬁcantly
reduced the AGE formation and secretion, the levels of N-(car-
boxymethyl) lysine, and the expression of RAGE in the diabetic
kidney. KRG also prevented the streptozotocin-induced destruc-
tion of glomerular structure and signiﬁcantly suppressed HG-
induced ﬁbronectin production [17]. In this study, we found thatGTS downregulated the RAGE levels in podocytes, which could
explain the protective role of ginseng substances on diabetic
glomerular pathology.
Although the renoprotective effect of ginseng components in
diabetic models has been reported, there were a few reports which
elucidated the changes of glomerular ﬁltration structures. Focusing
on glomerular ﬁltration structures, ginsenoside Rgl improved the
diabetic pathological changes of glomerular ﬁltration, such as GBM
thickness and podocytopenia with the reduction of urine protein
and serum creatine [29]. Ginsenoside Rgl also improved the over-
expressed levels of serum monocyte chemotactic protein-1 and
tumor necrosis factor-a, which correlated with the improved clin-
ical and pathological indices. Each gram of GTS, assayed by HPLC
and provided by Korea Ginseng Corporation, contains Rg1
(94.6 mg), Re (87.0 mg), Rf (28.5 mg), Rh1 (5.6 mg), Rg2 (23.7 mg),
Rb1 (161.6 mg), Rc (81.1 mg), Rb2 (76.9 mg), Rd (39.7 mg), Rg3
(22.5 mg), and Rh2 (24.8 mg). The effects of each GTS component
on the glomerular structure in the pathological condition need to
be examined.
Recently, we reported that in vitro diabetic conditions induced
the distributional change and suppressed the production of ZO-1
[19], p130Cas [20], and b-catenin [21], which adapted the slit dia-
phragm and the GBM to the cytoskeleton. We also found that such
distributional and quantitative changes in ZO-1 were associated
with podocyte hyperpermeability at early incubation times (2e8 h)
[19], however, there were no signiﬁcant changes in a-actinin-4 at
6 h incubation in this study. The apparent decreases in a-actinin
protein were observed at 24 h and 48 h. We therefore suggest that
in vitro diabetic conditions induced the distributional and quanti-
tative changes of adaptor proteins at an early stage, causing
podocyte hyperpermeability, and thereafter distributional and
quantitative changes in the cytoskeletal proteins.
In this study, we found that in an in vitro diabetic milieu, both
HG and AGE induced the cytoplasmic translocation and suppressed
the production of a-actinin-4, which could be mitigated by GTS
(Fig. 4); therefore GTS would be helpful in the prevention of cyto-
skeletal changes of podocytes in diabetic nephropathy.
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